BIOAVAILABILITAS DISPERSI PADAT QUERCETIN-HPMC PADA KELINCI

Quercetin belongs to the Biopharmaceutics Classification System (BCS) II, therefore modifying the quercetin formulation will affect the bioavailability. In this study, quercetin was modified by adding HPMC to the quercetin as stabilizer of amorphous form of quercetin solid dispersion system. The bioavailability profile of the 250mg/kg doses of quercetin was investigated in 6 rabbits. Quercetin was administered under two condition : single quercetin as control and solid dispersion quercetin- HPMC. The concentration of quercetin in plasma were determined by a validated high performance liquid chrmatography method. Bioavailability parameters including Tmax, Cmax and AUC0-480 were determined. In control group, the average value of Tmax, Cmax, AUC0-480 were 30 min, and 0.40 ± 0.23 g/mL, 44.40 ± 39.42 g.minutes/mL, respectively Tmax, Cmax and AUC0-480 of quercetin after the administration of solid dispersion were 15 min, 0.44 ± 0.23 g/mL, 52.46 ± 35.96 g.minutes/mL respectively there was slight, but not significant increase in Cmax and AUC0-480 after administration of quercetin-HPMC as compared to quercetin alone. It can be concluded that HPMC can accelerate Tmax but not change the bioavailability of quercetin showed by Cmax and AUC0-480